Vascugenix Prepares to Launch Speed-Torque Device: Designed to Improve the Process of Guidewire Manipulation in Cardiovascular Procedures

Vascugenix is a medical device company focused on developing innovative products to improve interventional cardiovascular procedures, is preparing to launch its first developed device, the Speed-Torque, in the U.S. market.

Vascugenix notes the Speed-Torque is specially designed to improve the process of guidewire manipulation in cardiovascular procedures. The patented design allows physicians to easily manipulate a guidewire with one hand, unlike traditional guidewire torque devices that require two hands to advance and reposition.

The Vascugenix team partnered with Gilero, a medical device design, development, and manufacturing company, to take this novel product idea from concept to commercialization.

“Vascugenix has worked closely with Gilero over the past nine months to develop and commercialize the Speed-Torque. Bringing a new device to the market during the COVID pandemic has been challenging, but Gilero and Vascugenix have worked closely together to make it happen,” says Martial Trigeaud, Chief Operating Officer for Vascugenix.

“Thanks to the dedication of Gilero, as well their Shenzhen-based injection molding partner Medacys, we were able to fully develop this device and bring it to market in a relatively short period of time,” adds Trigeaud. “The team at Vascugenix is excited to bring this product to market. The Speed-Torque will ultimately save physicians time, hospitals money, and improve patient safety.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”